- Home
- / Aeglea
Aeglea
Stock Price
$27.7
2024-01-29
Market Capitalization
$48.6 M
2024-01-29
Revenue
$886 K
FY, 2023
Aeglea Summary
Company Summary
- Overview
- Aeglea BioTherapeutics is a biotechnology company committed to developing enzyme-based therapeutics. It specializes in the field of amino acid metabolism to treat rare genetic diseases and cancer.
- Type
- Public
- Status
- Active
- Founded
- 2013
- HQ
- Austin, TX, US | view all locations
- Website
- https://www.aeglea.com/
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
Cortney Caudill, Chief Product Officer
Joseph E. Tyler, Vice President of Manufacturing
Linda Neuman, Chief Medical Officer
Aeglea Financials
Summary Financials
- Net income (Q1, 2025)
- ($44.8M)
- Cash (Q1, 2025)
- $48.5M
- EBIT (Q1, 2025)
- ($53.6M)